Details of Disease

General Information of Disease (ID: DISWYLB3)

Disease Name Pediatric cancer
Disease Class 2A00-2F9Z: Solid tumour/cancer
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISWYLB3: Pediatric cancer
ICD Code
ICD-11
ICD-11: 2A00-2F9Z
ICD-10
ICD-10: C00-C96
ICD-9
ICD-9: 140-229
Expand ICD-9
140,141,142,143,144,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000
Disease Identifiers
MONDO ID
MONDO_0003659
UMLS CUI
C1332979
MedGen ID
232062

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Armodafinil DMGB035 Approved Small molecular drug [1]
Immune globulin DMX2OMJ Approved NA [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Encepur DME1IHK Phase 3 NA [3]
Pixantrone DMQGR45 Phase 3 Small molecular drug [4]
Rotavirus vaccine DMDME06 Phase 3 NA [5]
CLR-131 DMDM2DF Phase 2 NA [4]
HuCART-meso cells DM4F8AU Phase 1 CAR T Cell Therapy [6]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 2 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Chondrogel DMBL23J Discontinued in Phase 3 NA [7]
Oxibendazole DMWPT8J Discontinued in Phase 3 Small molecular drug [8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 ClinicalTrials.gov (NCT00110708) Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT00161824) Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Sanofi Pasteur.
6 ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017047)
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018000)